| |
|
Product Name:
|
Monoclonal Anti-Influenza Virus H9 Hemagglutinin (HA) Protein (G1-26), A/quail/Hong Kong/G1/1997 (H9N2) (ascites, Mouse)
|
|
Ownership statement:
|
This reagent is the property of the U.S. Government.
|
|
Manufacturer:
|
St. Jude Children’s Research Hospital (CEIRS)
|
|
Material Provided:
|
Each vial of NR-9485 contains lyophilized (0.2 mL containing 0.02% sodium azide and 0.01% gentamycin) mouse ascites fluid.
|
|
Packing/Storage:
|
NR-9485 was packaged in glass serum vials with an aluminum crimp seal. The product is provided frozen and should be stored at -20°C to -40°C immediately upon arrival. Storage at warmer temperatures is not recommended due to a low bioburden. At colder temperatures, the rubber stopper may become brittle and compromise the seal. NR-9485 should be reconstituted with 1.0 mL of sterile distilled water. Reconstituted material should be stored at -20°C to -40°C. Reconstituted material may be thawed at room temperature and should be re-frozen.
|
|
Functional Activity:
|
NR-9485 is specific for the H9 HA subtype of the influenza A virus as determined in standard hemagglutination inhibition (HI) assays. NR-9485 also demonstrates reactivity within the H9 HA subtype. HI titers with 20 different influenza strains of the H9 HA subtype representing Eurasian and North American lineages, as well as H9 HA viruses from other geographic areas, are shown on the Certificate of Analysis. No reactivity was observed with several viruses of North American lineage.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Xu, K. M., et al. “Evolution and Molecular Epidemiology of H9N2 Influenza A Viruses from Quail in Southern China, 2000 to 2005.” J. Virol. 81 (2007): 2635-2645. PubMed: 17192315.
2. Butt, K. M., et al. “Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003.” J. Clin. Microbiol. 43 (2005): 5760-5767. PubMed: 16272514.
3. Choi, Y. K., et al. “Continuing Evolution of H9N2 Influenza Viruses in Southeastern China.” J. Virol. 78 (2004): 8609-8614. PubMed: 15280470.
4. Kaverin, N. V., et al. “Structural Differences among Hemagglutinins of Influenza A Virus Subtypes are Reflected in Their Antigenic Architecture: Analysis of H9 Escape Mutants.” J. Virol. 78 (2004): 240-249. PubMed: 14671105.
5. Guan, Y., et al. “Molecular Characterization of H9N2 Influenza Viruses: Were They the Donors of the "Internal" Genes of H5N1 Viruses in Hong Kong?” Proc. Natl. Acad. Sci. USA 96 (1999): 9363-9367. PubMed: 10430948. GenPept: AAF00701.
6. Saito, T., W. Lim. and M. Tashiro. “Attenuation of a Human H9N2 Influenza Virus in Mammalian Host by Reassortment with an Avian Influenza Virus.” Arch. Virol. 149 (2004): 1397-1407. PubMed: 15221539.
7. Guo, Y. J., et al. “Characterization of the Pathogenicity of Members of the Newly Established H9N2 Influenza Virus Lineages in Asia.” Virology 267 (2000): 279-288. PubMed: 10662623.
8. Saito, T., et al. “Characterization of a Human H9N2 Influenza Virus Isolated in Hong Kong.” Vaccine 20 (2001): 125-133. PubMed: 11567756.
9. Li, K. S., et al. “Characterization of H9 Subtype Influenza Viruses from the Ducks of Southern China: A Candidate for the Next Influenza Pandemic in Humans?” J. Virol. 77 (2003): 6988-6994. PubMed: 12768017.
10. Liu, J., et al. “H9N2 Influenza Viruses Prevalent in Poultry in China are Phylogenetically Distinct from A/quail/Hong Kong/G1/97 Presumed to be the Donor of the Internal Protein Genes of the H5N1 Hong Kong/97 Virus.” Avian Pathol. 32 (2003): 551-560. PubMed: 14522712.
11. Guan, Y., et al. “H9N2 Influenza Viruses Possessing H5N1-Like Internal Genomes Continue to Circulate in Poultry in Southeastern China.” J. Virol. 74 (2000): 9372- 9380. PubMed: 11000205.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Influenza Virus H9 Hemagglutinin (HA) Protein (G1-26), A/quail/Hong Kong/G1/1997 (H9N2) (ascites, Mouse), NR-9485."
|
|
Biosafety Level:
|
1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|